Related Experiment Video
Updated: Apr 12, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor
Regina Lin1, John H Sampson2, Qi-Jing Li1
1Department of Immunology; Duke University Medical Center ; Durham, NC, USA.
In adoptive T cell transfer therapy (ACT), the antitumor efficacy of cytotoxic CD8+ T lymphocytes (CTLs) has been limited by tumor-induced immunosuppression. We have demonstrated that miR-23a blockade in tumor-specific CTLs conferred resilience to TGFβ-mediated immunosuppression, resulting in superior tumor control. Our studies highlight miR-23a in tumor-specific CTLs as a clinically relevant target to enhance ACT.
In adoptive T cell transfer therapy (ACT), the antitumor efficacy of cytotoxic CD8+ T lymphocytes (CTLs) has been limited by tumor-induced immunosuppression. We have demonstrated that miR-23a blockade in tumor-specific CTLs conferred resilience to TGFβ-mediated immunosuppression, resulting in superior tumor control. Our studies highlight miR-23a in tumor-specific CTLs as a clinically relevant target to enhance ACT.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...

